Q-omics provides the consensus-scored FAM120B profile across patient tissues and cancer cell-line models. FAM120B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, FAM120B is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, FAM120B RNA expression shows 21,467 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight OV, THCA, and ACC as cancer lineages where FAM120B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM120B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM120B survival associations across molecular data types. FAM120B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM120B RNA expression–survival associations across cancer types. High FAM120B expression shows unfavorable associations in OV and BLCA, but favorable associations in KIRC, SCLC, LGG and PAAD. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for FAM120B RNA expression.
This table summarizes FAM120B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FAM120B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM120B shows lower tumor expression in THCA, KICH and COAD and higher tumor expression in HNSC, LIHC and CHOL. The THCA box plot shows higher FAM120B RNA expression in normal versus tumor tissue (log2 FC = −0.891, t-test p < 0.001).
This table shows molecular features associated with FAM120B in patient tissues and cancer cell lines. In patient samples, FAM120B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM120B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
